Biocryst Pharmaceuticals, Inc.

From Biocryst Pharmaceuticals's results release of 4 listopada 2026; its quarterly report has since been filed.

• Revenue

  Actual

  180,3M USD

  +13% y/y ↑
  -17% q/q ↓

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  0,14 USD

  +133% y/y ↑
  -53% q/q ↓

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  53,3M USD

  +80% y/y ↑
  -46% q/q ↓

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.